Poseida Therapeutics, Inc. (NASDAQ:PSTX) Stake Boosted by Barclays PLC

Barclays PLC increased its position in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 132.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 120,464 shares of the company’s stock after buying an additional 68,688 shares during the quarter. Barclays PLC’s holdings in Poseida Therapeutics were worth $345,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Renaissance Technologies LLC raised its stake in shares of Poseida Therapeutics by 53.4% during the 2nd quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock worth $2,496,000 after purchasing an additional 297,500 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Poseida Therapeutics by 62.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 359,197 shares of the company’s stock worth $1,027,000 after buying an additional 138,510 shares during the last quarter. Blair William & Co. IL raised its position in Poseida Therapeutics by 14.1% during the second quarter. Blair William & Co. IL now owns 1,101,325 shares of the company’s stock valued at $3,216,000 after acquiring an additional 136,273 shares in the last quarter. Fred Alger Management LLC acquired a new stake in Poseida Therapeutics in the third quarter valued at approximately $369,000. Finally, Advantage Alpha Capital Partners LP acquired a new stake in Poseida Therapeutics in the third quarter valued at approximately $285,000. Institutional investors and hedge funds own 46.87% of the company’s stock.

Poseida Therapeutics Stock Performance

NASDAQ:PSTX opened at $9.50 on Monday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.20 and a current ratio of 3.20. The firm’s 50-day moving average is $8.04 and its 200-day moving average is $4.71. Poseida Therapeutics, Inc. has a 52-week low of $1.87 and a 52-week high of $9.67. The company has a market cap of $928.85 million, a price-to-earnings ratio of -15.08 and a beta of 1.63.

Insider Activity at Poseida Therapeutics

In other Poseida Therapeutics news, Chairman Mark J. Gergen sold 30,000 shares of Poseida Therapeutics stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $9.27, for a total transaction of $278,100.00. Following the sale, the chairman now owns 651,291 shares in the company, valued at $6,037,467.57. The trade was a 4.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 2.90% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on PSTX. Cantor Fitzgerald downgraded shares of Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 26th. Piper Sandler downgraded Poseida Therapeutics from an “overweight” rating to a “neutral” rating and set a $10.00 price target on the stock. in a report on Monday, December 2nd. HC Wainwright reiterated a “neutral” rating and issued a $9.00 target price (down from $20.00) on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. William Blair reissued a “market perform” rating on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. Finally, BTIG Research restated a “neutral” rating on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $9.50.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.